SPRC Stock Chart & Stats
$4.42
-$0.23(-22.16%)
At close: 4:00 PM EST
$4.42
-$0.23(-22.16%)
Day’s Range― - ―
52-Week Range$2.98 - $80.10
Previous CloseN/A
Volume2.49M
Average Volume (3M)207.26K
Market Cap
$2.95M
Enterprise Value-$3.76M
Total Cash (Recent Filing)$4.59M
Total Debt (Recent Filing)$366.00K
Price to Earnings (P/E)―
Beta1.64
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-231.49
Shares Outstanding573,243
10 Day Avg. Volume21,771
30 Day Avg. Volume207,260
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)39.84
Price to Sales (P/S)197.30
P/FCF Ratio-40.82
Enterprise Value/Market Cap-1.27
Enterprise Value/Revenue-4.39
Enterprise Value/Gross Profit-9.47
Enterprise Value/Ebitda0.44
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-6,044.22
Revenue Forecast (FY)N/A
SciSparc Ltd. News
SPRC FAQ
What was SciSparc Ltd.’s price range in the past 12 months?
SciSparc Ltd. lowest stock price was $2.98 and its highest was $80.10 in the past 12 months.
What is SciSparc Ltd.’s market cap?
SciSparc Ltd.’s market cap is $2.95M.
When is SciSparc Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were SciSparc Ltd.’s earnings last quarter?
Currently, no data Available
Is SciSparc Ltd. overvalued?
According to Wall Street analysts SciSparc Ltd.’s price is currently Overvalued.
Does SciSparc Ltd. pay dividends?
SciSparc Ltd. does not currently pay dividends.
What is SciSparc Ltd.’s EPS estimate?
SciSparc Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SciSparc Ltd. have?
SciSparc Ltd. has 573,243 shares outstanding.
What happened to SciSparc Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of SciSparc Ltd.?
Currently, no hedge funds are holding shares in SPRC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SciSparc Ltd.
SciSparc Ltd. is a pharmaceutical company in the clinical development phase, specializing in creating medications derived from cannabinoid molecules. Their therapeutic pipeline encompasses several key drug candidates: SCI-110, which is being investigated for the treatment of Tourette syndrome, obstructive sleep apnea, and agitation associated with Alzheimer's disease; SCI-160, designed to address pain; and SCI-210, targeting autism spectrum disorder and epilepsy. The company has formed strategic alliances to further its goals. A partnership with Procaps focuses on the development and eventual commercial manufacturing of SCI-110, as well as CannAmide, an oral palmitoylethanolamide in a soft gel capsule. SciSparc is also collaborating with the Sheba Fund for Health Services and Research to explore SCI-210's potential in managing status epilepticus. Additionally, it has teamed up with The Israeli Medical Center for Alzheimer's to conduct a Phase IIa clinical trial, evaluating the safety, tolerability, and effectiveness of SCI-110 for patients experiencing Alzheimer's disease and agitation. Founded in 2004, the company initially operated under the name Therapix Biosciences Ltd. before changing to SciSparc Ltd. in January 2021. Its main corporate office is located in Tel Aviv-Yafo, Israel.
Technical Analysis
Ownership Overview
Options Prices
Currently, No data available
---